痰
结核分枝杆菌
结核分枝杆菌复合物
DNA提取
分析灵敏度
生物
聚合酶链反应
肺结核
微生物学
分子生物学
基因组DNA
检出限
DNA
基因
医学
色谱法
化学
遗传学
病理
替代医学
作者
Jennifer L. Reed,Zachary J. Walker,Debby Basu,Veronica Allen,Mark P. Nicol,David M. Kelso,Sally M. McFall
出处
期刊:Tuberculosis
[Elsevier BV]
日期:2016-09-12
卷期号:101: 114-124
被引量:27
标识
DOI:10.1016/j.tube.2016.09.002
摘要
Nucleic acid amplification tests for Mycobacterium tuberculosis (MTB) detection from sputum are highly sensitive and specific with smear microscopy positive specimens, but their sensitivity with smear-negative/culture-positive specimens is much lower; therefore, these tests cannot rule out a tuberculosis diagnosis. Co-extraction of PCR inhibitors may be a cause of decreased test sensitivity. Here the design and early validation of a MTB screening assay with sample preparation and qPCR methods designed to specifically address this diagnostic gap is reported. First, human genomic DNA is identified as a significant qPCR inhibitor. To circumvent this problem, a novel, streamlined sample preparation method utilizing detergent and proteolysis to thin the sputum and DNA sequence specific MTB DNA isolation was developed. Additionally, a multiplexed qPCR assay targeting two MTB complex-specific loci: the potentially multi-copy IS6110 and the single-copy senX3-regX3, combined with the cotJC gene from Bacillus atrophaeus spores amplified as a process control was developed. The limit of detection of the test was estimated to be 20 cfu/ml which is significantly lower than the Xpert® MTB/RIF assay. In a preliminary field study of 60 de-identified blinded sputa, a test sensitivity of 96% and specificity of 100% was observed when compared to the Xpert® MTB/RIF assay.
科研通智能强力驱动
Strongly Powered by AbleSci AI